uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung

Study Purpose

uPAR PET/CT as a prognostic marker in non-small cell lung cancer.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years - 85 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

Study
  • I. - Histologically verified NSCLC (Study I) - Stage IV disease.
  • - Operable disease.
  • - The participants must be capable of understanding and giving full informed written consent.
Study
  • II. - Histologically verified MPM (Study II) - The participants must be capable of understanding and giving full informed written consent.
Study
  • III. - Histologically verified LCNEC (Study III) - The participants must be capable of understanding and giving full informed written consent.

Exclusion Criteria:

Study I, II,
  • III. - Pregnancy.
  • - Lactation/breast feeding.
  • - Treatment with neoadjuvant chemotherapy.
  • - Weight above 140 kg.
- Allergy to 68Ga-NOTA-AE105

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT02755675
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Rigshospitalet, Denmark
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Recruiting
Countries Denmark
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma, Large Cell Neuroendocrine Carcinoma of the Lung
Additional Details

Study I: uPAR PET/CT with 68Ga-NOTA-AE105 will be evaluated as a prognostic tool in patients with non-small cell lung cancer (NSCLC) (stage IV (Ia) operable disease (Ib)) by observer-blinded readings and compared to the prognostic performance of FDG PET/CT and prognostic biomarkers as uPAR. Furthermore, uPAR PET/CT will be evaluated in a pilot study in patients with malignant pleural mesothelioma (MPM) (Study II) and large cell neuroendocrine carcinoma of the lung (LCNEC) (Study III) and correlated with immunohistochemical uPAR expression.

Arms & Interventions

Arms

Experimental: 68Ga-NOTA-AE105 PET/CT

One injection of 68Ga-NOTA-AE105 followed by positron emission tomography/computed tomography (PET/CT scan) will be performed before treatment start to evaluate the prognostic value of uPAR PET/CT.

Interventions

Other: - 68Ga-NOTA-AE105 PET/CT

Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/CT

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Copenhagen, Denmark

Status

Recruiting

Address

Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet

Copenhagen, , 2100

Site Contact

Malene M Clausen, MD, PhD

malene.martini.clausen@regionh.dk

+4522524536

Stay Informed & Connected